Therapeutic Challenges in Neuroendocrine Tumors

Anticancer Agents Med Chem. 2017;17(7):902-919. doi: 10.2174/1871520617666170213113401.


Neuroendocrine tumors (NETs) are a diverse set of tumors, being genetically varied. NETs can be presented with a distinct clinical picture, due to the production of various hormones, or being silent. Based on community health clinical statistics, the frequency numbers and reported occurrence of NETs are increasing. Although the therapeutic options for NETs have expanded in recent years, clinical diagnosis is possible only when metastases are present, requiring chronic complicated medical management. A positive development is that the recent evolution of molecularly-targeted therapy in oncology promotes the evolution of innovative tools for the management of these tumors. A diverse assortment of medical specialists is needed to improve outcomes and orchestrate the therapeutic care plan for NET patients.

Keywords: Neuroendocrine tumors; angiogenesis inhibitors; biomarkers; cytotoxic chemotherapy; liver-targeted therapies; radionuclide therapy; somatostatin analogs.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / analysis
  • Humans
  • Interferons / therapeutic use
  • Molecular Targeted Therapy
  • Neuroendocrine Tumors / diagnosis*
  • Neuroendocrine Tumors / drug therapy*
  • Radioisotopes / therapeutic use
  • Somatostatin / analogs & derivatives
  • Somatostatin / therapeutic use
  • TOR Serine-Threonine Kinases / antagonists & inhibitors


  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Radioisotopes
  • Somatostatin
  • Interferons
  • TOR Serine-Threonine Kinases